Quote | Acumen Pharmaceuticals Inc. (NASDAQ:ABOS)
Last: | $2.31 |
---|---|
Change Percent: | -0.84% |
Open: | $2.39 |
Close: | $2.31 |
High: | $2.39 |
Low: | $2.26 |
Volume: | 263,211 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Acumen Pharmaceuticals Inc. (NASDAQ:ABOS)
2024-05-14 12:46:06 ET Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Conference Call May 14, 2024 08:00 ET Company Participants Alex Braun - Vice President & Head of Investor Relations Daniel O’Connell - Chief Executive Officer Matt Zuga - Chief...
2024-05-14 07:01:38 ET More on Acumen Pharmaceuticals Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for...
Message Board Posts | Acumen Pharmaceuticals Inc. (NASDAQ:ABOS)
Subject | By | Source | When |
---|---|---|---|
Down over 50% from yearly highs and still | Moonboy1 | investorshub | 12/02/2022 11:21:07 AM |
One penny away haha. That's amazing. Charts never lie. | Moonboy1 | investorshub | 10/27/2022 10:29:02 PM |
Almost there. | Moonboy1 | investorshub | 10/26/2022 1:27:44 AM |
Getting close to my buy price. 6s probably today | Moonboy1 | investorshub | 10/21/2022 12:16:26 PM |
I'm a buyer under $7. Just going by | Moonboy1 | investorshub | 10/19/2022 1:43:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalent...
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...